N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): preparation and storage
Intended for research use only. Not a medicinal product.
Contents (7 sections)
Ac-SDKP: an acetylated tetrapeptide
Ac-SDKP means N-acetyl-Ser-Asp-Lys-Pro. N-terminal acetylation is part of its structure, so unacetylated SDKP is not an equivalent substitute. Early work identified this haemoregulatory peptide’s structure; a separate biochemical study established cleavage by the N-terminal active site of angiotensin-converting enzyme. This enzymatic context matters for exposure design but does not define a dry powder’s shelf life.
For cell or enzyme assays record the ACE source, serum composition and any inhibitors. An ACE inhibitor may preserve Ac-SDKP while independently affecting the model, requiring an inhibitor-only control. Distinguish the original acetylated peptide from cleavage products in analytical measurements. Total amino-group signal or residue mass does not establish intact Ac-SDKP. Consider measuring analyte recovery at the start and end of exposure in the actual working medium.
To investigate degradation compare time courses in buffer and working matrix at the same initial concentration. Differences reveal matrix effects but do not alone identify a particular enzyme. Use a suitable internal standard and verify that reaction quenching does not destroy the analyte. Residual inhibitor or acid from preparation requires its own cell-assay control. Findings apply to the stated medium composition and temperature rather than every aqueous Ac-SDKP solution.
Two primary studies answer different questions
Lenfant and colleagues isolated a hematoregulatory factor in 1989 and identified its structure as an acetylated tetrapeptide. This supports checking N-acetylation rather than treating any SDKP as equivalent. In a stem cell experiment, reduced proliferation must be distinguished from toxicity: measure cell number and viability separately. Structural identification does not establish universal dissolution conditions for commercial material.
In 1995, Rousseau and colleagues compared recombinant wild-type ACE with variants having one functional active site. Both sites cleaved Ac-SDKP, but the N-terminal site was substantially more efficient; its predominant role was also checked with a specific antibody. This comparison explains why ACE source and domain composition matter in a protocol. Purified enzyme solution and a serum matrix are different systems.
Reagent form and stock preparation
For N-acetyl-Ser-Asp-Lys-Pro, check the COA for the terminal carboxyl group, counterion and water as well as mass. N-terminal acetylation does not eliminate all amino groups: the lysine side chain remains a separate functional group. A general amine colorimetric assay is therefore not specific confirmation of intact Ac-SDKP concentration. Molar calculations require the molecular weight of the verified form.
Take a small trial portion and check dissolution in the aqueous vehicle specified by your method. Record final pH because acidity affects both peptide charge and enzyme reaction. Do not transfer an acidic stock to an ACE assay without assessing the final acid fraction. If the matrix contains a protease inhibitor or chelator, establish its effect on metal-dependent ACE before interpreting absent cleavage as a batch property.
Mass balance in an enzyme assay
An arithmetic example: verified 0.900 mg of Ac-SDKP in a final 1.80 ml gives 0.500 mg/ml. For 1.00 ml of a 0.0250 mg/ml working solution, take 50.0 µl of stock and add vehicle to 1000 µl. After mixing 80 µl of working solution with 20 µl of enzyme solution, the initial substrate concentration is 0.0200 mg/ml. This example does not select a kinetic concentration for a particular ACE preparation.
To plot rate against substrate concentration, establish molarity after confirming chemical form rather than using mass concentrations interchangeably with µM. Keep final buffer and enzyme amount identical across the series. Count time zero from mixing rather than the start of instrument injection. Otherwise, different sample delays can resemble different hydrolysis rates.
Stopping the reaction and analytical specificity
Timed samples require a verified ACE quenching procedure. It must stop the reaction, preserve the analyte and avoid creating different matrix effects between time points. Compare standard addition before and after sample preparation. Loss after protein precipitation can reflect analyte removal with the pellet rather than biological degradation. Cold alone should not be assumed to stop the enzyme fully and instantly.
For HPLC or LC-MS, check separation of intact Ac-SDKP from fragments, along with standard and signal agreement. An internal standard helps account for losses only when its behavior during preparation suits the question. Include substrate without enzyme, enzyme without substrate and inhibitor without peptide. For a cellular endpoint, carryover of ACE inhibitor to the next stage must be matched or controlled.
Aliquots and practical questions
Does an ACE inhibitor preserve a stock? In a biological matrix it may reduce enzymatic conversion, but it creates another reagent with its own biological action. Do not automatically add it to a pure stock. Can nonacetylated SDKP be used? It is a different substrate; equal mass does not make it an intact Ac-SDKP control. Does total peptide mass prove preservation? Fragments also remain in solution.
Keep dry material at the verified labelled temperature; refrigerated or frozen solution storage requires a corresponding specification. Stability in clean buffer does not establish stability in serum containing ACE. Label aliquots with the acetylated form, vehicle, pH and time, and measure intact peptide when checking them. General aliquot requirements appear in the storage guide; the specific concern here is enzyme exposure.
End of article
AC-SDKP
for laboratory research
Packs and current prices on the product page.